MARKET

NKTR

NKTR

Nektar
NASDAQ

Real-time Quotes | Nasdaq Last Sale

16.80
-0.07
-0.39%
Opening 12:27 06/22 EDT
OPEN
16.80
PREV CLOSE
16.86
HIGH
16.94
LOW
16.56
VOLUME
213.22K
TURNOVER
--
52 WEEK HIGH
26.75
52 WEEK LOW
15.40
MARKET CAP
3.06B
P/E (TTM)
-7.0416
1D
5D
1M
3M
1Y
5Y
Exelixis (EXEL) & Bristol Myers Team Up for Genitourinary Cancers
Zacks.com · 06/15 15:39
Exelixis inks collaboration and supply agreement with Bristol Myers Squibb for cancer study
Exelixis (EXEL) announces a clinical trial collaboration and supply agreement with Bristol-Myers Squibb (BMY) for STELLAR-002, a new phase 1b trial evaluating XL092 in combination with immuno-oncology therapies in advanced solid
Seekingalpha · 06/14 12:33
Exelixis Announces Clinical Trial Collaboration and Supply Agreement with Bristol Myers Squibb to Evaluate XL092 in Combination with Immuno-oncology Therapies in Advanced Solid Tumors
Exelixis, Inc. (Nasdaq: EXEL) today announced a clinical trial collaboration and supply agreement with Bristol-Myers Squibb Company (NYSE: BMY) for STELLAR-002, a new phase 1b trial evaluating XL092 in combination with immuno-oncology therapies in advanced...
Business Wire · 06/14 12:00
Exelixis Working With Bristol-Myers to Launch Early-Stage Study of Potential Tumor Drug XL092
MT Newswires · 06/14 08:37
Ra Medical Systems, Liminal BioSciences leads healthcare gainers; Cabaletta Bio, MacroGenics among major new losers
Gainers: Ra Medical Systems RMED +54%, Liminal BioSciences LMNL +42%, Atossa Therapeutics (ATOS) +27%, Bionano Genomics BNGO +20%, Clover Health Investments (CLOV) +16%.Losers: Cabaletta Bio (CABA) -10%, MacroGenics (MGNX) -8%, Purple Biotech (PPBT) -8%, I...
Seekingalpha · 06/07 15:02
Nektar Therapeutics to Participate in Fireside Chat at the Goldman Sachs 42nd Annual Global Healthcare Conference
/PRNewswire/ -- Nektar Therapeutics' (Nasdaq: NKTR) senior management is scheduled to participate in a virtual fireside chat at the upcoming Goldman Sachs 42 Annual Global Healthcare Conference on at .
PR Newswire - PRF · 06/07 12:30
Should Shareholders Reconsider Nektar Therapeutics' (NASDAQ:NKTR) CEO Compensation Package?
Nektar Therapeutics ( NASDAQ:NKTR ) has not performed well recently and CEO Howard Robin will probably need to up their...
Simply Wall St. · 06/04 14:46
We're Interested To See How Nektar Therapeutics (NASDAQ:NKTR) Uses Its Cash Hoard To Grow
Just because a business does not make any money, does not mean that the stock will go down. For example, although...
Simply Wall St. · 05/27 10:36
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of NKTR. Analyze the recent business situations of Nektar through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 12 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average NKTR stock price target is 31.10 with a high estimate of 80.00 and a low estimate of 20.00.
EPS
Institutional Holdings
Institutions: 425
Institutional Holdings: 201.26M
% Owned: 110.40%
Shares Outstanding: 182.31M
TypeInstitutionsShares
Increased
69
4.66M
New
25
2.27M
Decreased
85
8.14M
Sold Out
35
928.11K
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
-0.41%
Pharmaceuticals & Medical Research
-0.38%
Key Executives
Non-Executive Chairman/Independent Director
Robert Chess
Chief Executive Officer/President/Director
Howard Robin
Chief Financial Officer/Chief Operating Officer/Senior Vice President
Gilbert Labrucherie
Senior Vice President - Finance/Chief Accounting Officer
Jillian Thomsen
Senior Vice President/General Counsel
Mark Wilson
Senior Vice President
John Northcott
Other
Brian Kotzin
Other
Jonathan Zalevsky
Lead Director/Independent Director
Roy Whitfield
Independent Director
Jeff Ajer
Senior Vice President
Mary Tagliaferri
Independent Director
Myriam Curet
Independent Director
Karin Eastham
Independent Director
R. Scott Greer
No Data
  • All
  • Financials
  • Insiders
More
About NKTR
Nektar Therapeutics is a biopharmaceutical company. The Company discovers and develops medicines in areas of unmet medical need. Its research and development pipeline of new investigational drugs includes treatments for cancer and autoimmune disease. It has research and development (R&D) pipeline of medicines in oncology, immunology, and virology as well as a portfolio of approved partnered medicines. It leverages its chemistry platform to discover and design new drug candidates. These drug candidates utilize its polymer conjugate technology platforms, which are designed to enable the development of new molecular entities. Its R&D pipeline includes Bempegaldesleukin (NKTR-214), NKTR-358, NKTR-262 and NKTR-255. It develops medicines designed to modulate the activity of key immune cells, such as cytotoxic T cells and Natural Killer (NK) cells, to increase their numbers and improve their function to recognize and attack cancer cells directly or indirectly.

Webull offers kinds of Nektar Therapeutics stock information, including NASDAQ:NKTR real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, NKTR stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading NKTR stock methods without spending real money on the virtual paper trading platform.